The first battle happens in the blood vessels
A transplanted heart meets the recipient’s immune system immediately. Pig cells carry surface molecules that human antibodies can recognize as foreign. When those antibodies attach to the tiny blood vessels inside the heart, they can set off inflammation and clotting, damaging the organ before it has a chance to work. This fast, severe response is called hyperacute rejection.
To reduce that risk, researchers alter pig genes. Some edits remove or change pig-made molecules that human antibodies commonly target. Others add human genes that help regulate immune reactions and blood clotting. The goal is not to make the heart human, but to make its blood-vessel lining less likely to trigger an attack.
A working heartbeat is only the beginning
If the recipient’s blood can flow through the organ without an immediate rejection crisis, the heart can pump. But compatibility is a continuing problem, not a switch that genetic editing flips once. The immune system can still attack the transplanted tissue, and differences between pig and human biology can disrupt blood clotting or organ function over time.
Recipients therefore need intensive medical monitoring and drugs that suppress immune activity. Researchers also have to manage infection risks and watch for damage that may not appear in the first hours or days. Getting a pig heart to work initially shows that the species barrier can be crossed; keeping it working safely is the harder test.
